Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)

NCT01562301 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Chemotherapeutic Agent Toxicity
Lung Cancer

Interventions

DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Anvirzel
BEHAVIORAL: Questionnaires

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]